Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers

The OCEAN(a)-DOSE multicenter randomized clinical trial among 281 patients with atherosclerotic cardiovascular disease assesses the effects of olpasiran on oxidized phospholipids, high-sensitivity interleukin 6, and high-sensitivity C-reactive protein.